Importantly, the ex vivo screen also demonstrated that protein kinase inhibitors targeting JAK1, JAK2, aurora A, IGF1R and PLK suppressed cell growth of IR MCL cells (Fig. 6e). This evidence concerns the gene JAK1 and mantle cell lymphoma.